Disappointing interim results from a Phase III trial of its lead cancer drug, Canvaxin, prompted CancerVax Corp. to stop development of the drug and downsize the company's work force by more than half. (BioWorld Today)

Disappointing interim results from a Phase III trial of its lead cancer drug, Canvaxin, prompted CancerVax Corp. to stop development of the drug and downsize the company's work force by more than half. (BioWorld Today)